Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia

Leukemia Research

Volumn 27, Issue 7, 2003, Pages 661-669

  Verstovsek, Srdan ^a   Lunin, Scott ^a   Kantarjian, Hagop ^a   Manshouri, Taghi ^a   Faderl, Stefan ^a   Cortes, Jorge ^a   Giles, Francis ^a   Albitar, Maher ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiogenesis; Chronic myelogenous leukemia; Prognosis; VEGF receptors

Indexed keywords

VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; ARTICLE; BONE MARROW; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEPTOR UPREGULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLAST CRISIS; BONE MARROW; CASE-CONTROL STUDIES; DISEASE PROGRESSION; ENDOTHELIAL GROWTH FACTORS; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, MYELOID, CHRONIC; LYMPHOKINES; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0037411266     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(02)00275-8     Document Type: Article

References (65)

1. Folkman J. Tumor angiogenesis: therapeutic implications. New Engl. J. Med. 285:1971;1182-1186.
2. Folkman J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82:1990;4-6. [editorial].
3. Folkman J. The role of angiogenesis in tumor growth. Semin. Cancer Biol. 3:1992;65-71.
4. Gimbrone M.A. Jr., Leapman S.B., Cotran R.S., Folkman J. Tumor angiogenesis: iris neovascularization at a distance from experimental intraocular tumors. J. Natl. Cancer Inst. 50:1973;219-228.
5. Folkman J., Watson K., Ingber D., Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 339:1989;58-61.
6. Ellis L.M., Fidler I.J. Angiogenesis and metastasis. Eur. J. Cancer. 32A:1996;2451-2460.
7. Lundberg L.G., Lerner R., Sundelin P., Rogers R., Folkman J., Palmblad J. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am. J. Pathol. 157:2000;15-19.
8. Pruneri G., Bertolini F., Soligo D., Carboni N., Cortelezzi A., Ferrucci P.F.et al. Angiogenesis in myelodysplastic syndromes. Br. J. Cancer. 81:1999;1398-1401.
9. Vacca A., Ribatti D., Roncali L., Ranieri G., Serio G., Silvestris F.et al. Bone marrow angiogenesis and progression in multiple myeloma. Br. J. Haematol. 87:1994;503-508.
10. Vacca A., Ribatti D., Ruco L., Giacchetta F., Nico B., Quondamatteo F.et al. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br. J. Cancer. 79:1999;965-970.
11. Perez-Ataye A.R., Sallan S.E., Tedrow U., Connors S., Allred E., Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am. J. Pathol. 150:1997;815-821.
12. Hussong J.W., Rodgers G.M., Shami P.J. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood. 95:2000;309-313.
13. Padro T., Ruiz S., Bieker R., Burger H., Steins M., Kienast J.et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 95:2000;2637-2644.
14. Aguayo A., Kantarjian H., Manshouri T.et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 96:2000;2240-2245.
15. Bussolino F., Albini A., Camussi G., Presta M., Viglietto G., Ziche M.et al. Role of soluble mediators in angiogenesis. Eur. J. Cancer. 32A:1996;2401-2412.
16. Ferrara N. Vascular endothelial growth factor. Eur. J. Cancer. 32A:1996;2413-2422.
17. Basilico C., Moscatelli D. The FGF family of growth factors and oncogenes. Adv. Cancer Res. 59:1992;115-165.
18. Gualandris A., Urbinati C., Rusnati M., Ziche M., Presta M. Interaction of high-molecular-weight basic fibroblast growth factor with endothelium: biological activity and intracellular fate of human recombinant M(r) 24,000 bFGF. J. Cell Physiol. 161:1994;149-159.
19. Montesano R., Vassalli J.D., Baird A., Guillemin R., Orci L. Basic fibroblast growth factor induces angiogenesis in vitro. Proc. Natl. Acad. Sci. U.S.A. 83:1986;7297-7301.
20. Mignatti P., Tsuboi R., Robbins E., Rifkin D.B. In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases. J. Cell Biol. 108:1989;671-682.
21. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246:1989;1306-1309.
22. Keck P.J., Hauser S.D., Krivi G., Sanzo K., Warren T., Feder J.et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 246:1989;1309-1312.
23. Olofsson B., Pajusola K., Kaipainen A., von Euler G., Joukov V., Saksela O.et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 93:1996;2576-2581.
24. Joukov V., Pajusola K., Kaipainen A., Chilov D., Lahtinen I., Kukk E.et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 15:1996;1751.
25. Achen M.G., Jeltsch M., Kukk E., Makinen T., Vitali A., Wilks A.F.et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (flk1) and VEGF receptor 3 (flt4). Proc. Natl. Acad. Sci. U.S.A. 95:1998;548-553.
26. Yamada Y., Nezu J., Shimane M., Hirata Y. Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. Genomics. 42:1997;483-488.
27. Ogawa S., Oku A., Sawano A., Yamaguchi S., Yazaki Y., Shibuya M. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J. Biol. Chem. 273:1998;31273-31282.
28. Toi M., Hoshina S., Takayanagi T., Tominaga T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn. J. Cancer Res. 85:1994;1045-1049.
29. O'Brien T., Cranston D., Fuggle S., Bicknell R., Harris A.L. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res. 55:1995;510-513.
30. Takahashi Y., Kitadai Y., Bucana C.D., Cleary K.R., Ellis L.M. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 55:1995;3964-3968.
31. Vermeulen P.B., Gasparini G., Fox S.B., Toi M., Martin L., McCulloch P.et al. Quantification of angiogenesis in solid human tumors: an international consensus on the methodology and criteria of evaluation. Eur. J. Cancer. 32A:1996;2474-2484.
32. Gasparini G. Clinical significance of the determination of angiogenesis in human breast cancer: update of the biological background and overview of the Vicenza studies. Eur. J. Cancer. 32A:1996;2485-2493.
33. Chung Y.S., Maeda K., Sowa M. Prognostic value of angiogenesis in gastro-intestinal tumours. Eur. J. Cancer. 32A:1996;2501-2505.
34. Weidner N., Folkman J., Pozza F., Bevilacqua P., Allred E.N., Moore D.H.et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst. 84:1992;1875-1887.
35. Weidner N., Carroll P.R., Flax J., Blumenfeld W., Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. 143:1993;401-409.
36. Graham C.H., Rivers J., Kerbel R.S., Stankiewicz K.S., White W.L. Extent of vascularization as a prognostic indicator in thin (<0.76 mm) malignant melanomas. Am. J. Pathol. 145:1994;510-514.
37. Hollingsworth H.C., Kohn E.C., Steinberg S.M., Rothenberg M.L., Merino M.J. Tumor angiogenesis in advanced stage ovarian carcinoma. Am. J. Pathol. 147:1995;33-41.
38. Salven P., Teerenhovi L., Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood. 90:1997;3167-3172.
39. Aguayo A., Estey E., Kantarjian H., Manshouri T., Gidel C., Keating M.et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 94:1999;3717-3721.
40. Aguayo A., O'Brien S., Keating M., Manshouri T., Gidel C., Barlogie B.et al. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood. 96:2000;768-770.
41. Hayashibara T., Fujimoto T., Miyanishi T., Yamada Y., Maita T., Kamihira S.et al. Vascular endothelial growth factor at high plasma levels is associated with extranodal involvement in adult T cell leukemia patients. Leukemia. 13:1999;1634-1635. [letter].
42. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr. Top. Microbiol. Immunol. 237:1999;1-30.
43. Shibuya M., Ito N., Claesson-Welsh L. Structure and function of vascular endothelial growth factor receptor-1 and -2. Curr. Top. Microbiol. Immunol. 237:1999;59-83.
44. Veikkola T., Alitalo K. VEGFs. Semin. Cancer Biol. 9:1999;211-220.
45. Veikkola T., Karkkainen M., Claesson-Welsh L., Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 60:2000;203-212.
46. Xie B., Tam N.N., Tsao S.W., Wong Y.C. Co-expression of vascular endothelial growth factor (VEGF) and its receptors (flk-1 and flt-1) in hormone-induced mammary cancer in the Noble rat. Br. J. Cancer. 81:1999;1335-1343.
47. Abu-Jawdeh G.M., Faix J.D., Niloff J., Tognazzi K., Manseau E., Dvorak H.F.et al. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab. Invest. 74:1996;1105-1115.
48. Takanami I., Tanaka F., Hashizume T., Kodaira S. Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma. Anticancer Res. 17:1997;2811-2814.
49. Hahn D., Simak R., Steiner G.E., Handisurya A., Susani M., Marberger M. Expression of the VEGF-receptor flt-1 in benign. J. Urol. 164:2000;506-510.
50. Fiedler W., Graeven U., Ergun S., Verago S., Kilic N., Stockschlader M.et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood. 89:1997;1870-1875.
51. Katoh O., Tauchi H., Kawaishi K., Kimura A., Satow Y. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res. 55:1995;687-692.
52. Ratajczak M.Z., Ratajczak J., Machalinski B., Majka M., Marlicz W., Carter A.et al. Role of vascular endothelial growth factor (VEGF) and placenta-derived growth factor (PlGF) in regulating human haemopoietic cell growth. Br. J. Haematol. 103:1998;969-979.
53. Bellamy W.T., Richter L., Frutiger Y., Grogan T.M. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 59:1999;728-733.
54. Saclarides T.J., Speziale N.J., Drab E., Szeluga D.J., Rubin D.B. Tumor angiogenesis and rectal carcinoma. Dis. Colon Rectum. 37:1994;921-926.
55. Kim D.K., Watson R.C., Pahnke L.D., Fortner J.G. Tumor vascularity as a prognostic factor for hepatic tumors. Ann. Surg. 185:1977;31-34.
56. Revesz L., Siracka E. A morphometric study of vascularization in uterine cervix cancers. Cytometry. 5:1984;442-444.
57. Srivastava A., Hughes L.E., Woodcock J.P., Shedden E.J. The significance of blood flow in cutaneous malignant melanoma demonstrated by Doppler flowmetry. Eur. J. Surg. Oncol. 12:1986;13-18.
58. Revesz L., Siracka E., Balmukhanov S. Tumor vascularity: its possible prognostic and therapeutic value. Strahlenther. Onkol. 162:1986;639-641.
59. Van Hoef M.E., Knox W.F., Dhesi S.S., Howell A., Schor A.M. Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer. Eur. J. Cancer. 8:1993;1141-1145.
60. Vesalainen S., Lipponen P., Talja M., Alhava E., Syrjanen K. Tumor vascularity and basement membrane structure as prognostic factors in T1-2MO prostatic adenocarcinoma. Anticancer Res. 14:1994;709-714.
61. Maeda K., Chung Y.S., Ogawa Y., Ko T., Ogawa M., Onoda N.et al. Expression of vascular endothelial cell growth factor as a predictor of recurrence in gastric carcinoma. Gan To Kagaku Ryoho. 22:1995;699-701.
62. Dirix L.Y., Vermeulen P.B., Hubens G., Benoy I., Martin M., De Pooter C.et al. Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann. Oncol. 7:1996;843-848.
63. Crew J.P., O'Brien T., Bradburn M., Fuggle S., Bicknell R., Cranston D.et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res. 57:1997;5281-5285.
64. Hartenbach E.M., Olson T.A., Goswitz J.J., Mohanraj D., Twiggs L.B., Carson L.F.et al. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett. 121:1997;169-175.
65. Verstovsek S., Kantarjian H., Manshouri T., Cortes J., Giles F.J., Rogers A.et al. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood. 99:2002;2265-2267.